Answers are grounded in this paper and cite their sources.
Case report details effective adjuvant treatment for pancreatic squamous cell carcinoma, emphasizing its rarity and need for further research.
Pancreatic cancer (PC) has high morbidity and mortality rates, with a five-year survival rate of less than 10%. Within this spectrum,squamous cell carcinoma (SCC) of the pancreas stands out as a rare and aggressive form, representing between 0.5% and 2% ofdiagnosed cases. This report describes the case of a patient in whom a lesion in the body of the pancreas was incidentally identified,and he underwent a body and tail pancreatectomy. The diagnosis of pancreatic SCC was confirmed through anatomopathologicalexamination, adjuvant treatment with the FOLFIRINOX regimen was carried out and, after eight months of outpatient follow-up,there was no evidence of recurrence or progression of the disease. The rarity of this neoplasm impacts its management, highlightingthe need for more research to improve diagnosis and treatment and, consequently, the prognosis of patients.
No takes yet. Share an insight, caveat, or question.
Vm et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: